159184-13-1Relevant articles and documents
Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors
McDonnell, Mark E.,Bian, Haiyan,Wrobel, Jay,Smith, Garry R.,Liang, Shuguang,Ma, Haiching,Reitz, Allen B.
, p. 1116 - 1121 (2014/03/21)
We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid art
HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS
-
, (2008/06/13)
This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.